Regulatory & Legal

A UK regulatory filing reveals a hedge fund's bet against Qualcomm, questioning its major takeover and highlighting the surprising global reach of financial oversight.

From a Greenland mine to a Romanian refinery, a tech breakthrough is de-risking a vital new source of rare earths for the West's defense and green tech.

Hong Kong's JM Group raised $15M in a wild NYSE debut. We look past the volatility to see what this IPO reveals about global supply chains and risk.

Hedge fund Balyasny reveals a 1.26% economic stake in Just Group via derivatives, shining a light on the complex strategies at play in its takeover.

Cemtrex secures $2M for acquisitions, but a 15% stock drop and massive shareholder dilution reveal the high price of its ambitious growth strategy.

After years of delays, River Rock Capital Partners has taken over a stalled NC project, betting on unmet demand in one of the state's fastest-growing areas.

In a market tired of hype, investors are rewarding verifiable results. We explore the tech delivering hard proof, from quantum security to cancer therapies.

A new class of AI-driven blood tests can detect lung cancer recurrence years before imaging, shaking up patient care and the multi-billion dollar diagnostics market.

A potential $39M deal with Luminia positions NeoVolta to move from residential rooftops to utility-scale power, reshaping California's energy future.

S&P Global's latest report confirms Fluence's top-three status in the BESS market, driven by strategic execution and the surging demand for grid stability.

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

As quantum threats loom, SEALSQ's strategic entry into medical chips with post-quantum cryptography could redefine data security and the industry's supply chain.

Adagio Medical lands ex-Medtronic exec Sean Salmon. His mission: drive its novel cryoablation tech to disrupt the competitive cardiac arrhythmia market.

Beyond services, Charles River is building an ecosystem. We look at how its incubator nurtures startups and secures its own future in advanced medicine.

Beyond a simple acquisition, ZenaTech is executing a bold strategy to digitize the American West, transforming old-guard industries with a DaaS network.

In the heart of oil country, a new boom is taking shape. New Era Energy & Digital is building a gigawatt-scale AI campus, but can it win the infrastructure race?

The return of a critical antibiotic after 14 years via a new, ultra-fast FDA pathway signals a major shift in U.S. industrial and health policy.

Cadrenal Therapeutics acquires a novel Phase 2 drug for a deadly clotting disorder, a strategic move targeting an underserved $1 billion market.

Biomerica's regulatory win in Egypt is more than a market entry; it's a strategic move to disrupt healthcare with low-cost, rapid diagnostic tools.

byNordic Acquisition Corp. buys another month in its search for a Nordic tech merger, but each extension drains funds and tests investor patience.